Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir
about
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cellsEfficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivoPharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populationsInjectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1)Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza InfectionsSafety and efficacy of peramivir for influenza treatmentPeramivir (BCX-1812, RWJ-270201): potential new therapy for influenzaRWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenzaComparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza virusesBacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitorThe Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine ModelIota-carrageenan is a potent inhibitor of influenza A virus infectionPharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.Conformation and Linkage Studies of Specific Oligosaccharides Related to H1N1, H5N1, and Human Flu for Developing the Second Tamiflu.Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.Drugs in development for influenza.Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States.Pharmacokinetics of oseltamivir according to trimester of pregnancy.Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infectionPeramivir for the treatment of influenza.Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.Clinical use of approved influenza antivirals: therapy and prophylaxis.Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitorsNeuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replicationIn vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in miceCombinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.Animal Models for Influenza Virus Pathogenesis and Transmission.Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species.Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaquesPhase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.Economic evaluations of neuraminidase inhibitors to control influenza.Population pharmacokinetics of peramivir in healthy volunteers and influenza patients.Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteersEfficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system.
P2860
Q24559989-5869DC14-FBE5-4528-95D3-E22D3A272BBCQ24567591-7902C93F-4918-448D-92F7-20646B50D600Q24630906-4B568E36-97CD-4CF4-A5F1-6A145535C3F9Q24645944-DC1A803C-F6C6-486E-BDC0-FFC4CEEC5A0CQ26749578-A9589E2B-814D-4113-99EB-448D3BDAED2BQ27027408-117FC01F-66BF-4A9D-BEF7-161F49625660Q28201381-B9E6F3F9-6FD9-4F6D-8E1C-37B4A28EB151Q28344592-FC1B9BB2-7C74-4F0C-A81B-1972BF2CD728Q28364114-396CE640-9B4F-47FC-8828-BA0175445414Q28473051-4741FCF2-5E63-47C8-9E1B-DDD88333C0C8Q28483824-34E31BFF-9F6A-4BA7-8C34-577CB3AB5ABEQ28547982-3CDC04F4-96C6-41A1-AD92-79179ACC7B7EQ28744254-3FF0678E-CF24-44D9-AF17-C35F424EF30AQ30357189-94200055-4FDF-416E-B280-2D56EFBAEF21Q30361636-68DFCF6F-10D6-4D4F-8138-ABAD7FC47A70Q30385708-97448AD0-80BE-4E28-9956-226C0568605AQ30391218-D1A6DC6B-B5BF-4471-BAEE-5DB283438E11Q30400342-8838FBA3-E8E8-4BB4-8489-C9E6A8DCB1B5Q30401840-99475971-417E-42D4-9FBA-E9374A5FB3F7Q30408582-2E5AEB94-6829-4A11-B448-015ACAD66426Q30413154-A86F18A6-C36C-42AE-AE77-26F2D5AB6705Q30414428-2BF8E5ED-3974-409D-A853-C019E1086964Q30425343-B128FCB3-5491-46D1-8401-929FB8FED84DQ30450742-E81B7570-C149-45A7-A4C5-BFF236785847Q30452889-DBE48DD1-4614-47EF-99B5-FA23629AEDE1Q30453074-47C0A439-F33C-408A-8394-2E0564E9A087Q30453278-EBC2177E-8A75-45F2-AD22-C29066A4E558Q33761451-FCC9D895-24F9-407C-B269-378425F54BC9Q34159076-68DDE3A7-7E1B-4474-B0CA-D936812E9F16Q34483638-EFBA399E-8F82-4E74-B4AF-8C09625907B3Q34714853-9DAC2A8E-1AD7-4F60-AD51-B5F6B23FD5E1Q35005030-AA3A103E-1536-4CFF-8D2E-798247D28758Q35006918-596C50D8-C796-4795-A829-93E2E306B807Q35364037-B8F041DA-9FC3-4742-BFE6-4D094E8A5D80Q35364093-CBFD1182-EF1B-4B40-9ACD-B82830CAA557Q36020202-AC9712D2-B9C5-4D2E-8599-CCA9A4A5796DQ36158190-792C60FB-10AD-489E-893E-CF49B5894B61Q36172477-2BA4738B-FBDB-4FA6-AFD1-61F8ACFA8D38Q36785817-CEB327D9-B743-4824-AB59-11AE63DFF7F9Q37204154-0C42CB75-7317-4CDA-BC30-A7A950F48C8B
P2860
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Comparison of the anti-influen ...... e of oseltamivir and zanamivir
@ast
Comparison of the anti-influen ...... e of oseltamivir and zanamivir
@en
Comparison of the anti-influen ...... e of oseltamivir and zanamivir
@nl
type
label
Comparison of the anti-influen ...... e of oseltamivir and zanamivir
@ast
Comparison of the anti-influen ...... e of oseltamivir and zanamivir
@en
Comparison of the anti-influen ...... e of oseltamivir and zanamivir
@nl
prefLabel
Comparison of the anti-influen ...... e of oseltamivir and zanamivir
@ast
Comparison of the anti-influen ...... e of oseltamivir and zanamivir
@en
Comparison of the anti-influen ...... e of oseltamivir and zanamivir
@nl
P2093
P2860
P3181
P1476
Comparison of the anti-influen ...... e of oseltamivir and zanamivir
@en
P2093
A Dehghani
C D Parker
D L Kellog
J A Montgomery
P L Kotian
S L Ananth
P2860
P304
P3181
P356
10.1128/AAC.45.4.1162-1167.2001
P407
P577
2001-04-01T00:00:00Z